Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.

Benjamin J Solomon,Todd M Bauer,Sai-Hong Ignatius Ou,Geoffrey Liu,Hidetoshi Hayashi,Alessandra Bearz,Konstantin Penkov,Yi-Long Wu,Oscar Arrieta,Jacek Jassem,Anna M Calella,Gerson Peltz,Anna Polli,Holger Thurm,Tony Mok

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）

引用 32|浏览7

暂无评分

摘要

First-line lorlatinib improved PFS outcomes and reduced CNS progression versus crizotinib in patients with advanced -positive non-small-cell lung cancer with or without brain metastases at baseline. Half of all CNS AEs resolved without intervention or with lorlatinib dose modification.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要